XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Stock Options and Warrants | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
Stock Options and Warrants |
9. | Stock Options and Warrants
The Company periodically issues stock options and warrants to employees and non-employees in capital raising transactions, for services and for financing costs. Options and warrants vest and expire according to terms established at the grant date. Options Employee options vest according to the terms of the specific grant and expire from 5 to 10 years from date of grant. The weighted average, remaining contractual life of employee and non-employee options outstanding at December 31, 2023 was 3.9 years. Stock option activity for the period January 1, 2022 to December 31, 2023, was as follows:
Stock options outstanding |  |  |  |  |  |  |  |
|  | Options |  |  | Weighted Avg. Exercise Price |
Options outstanding, December 31, 2021 |  |  | 31,080,601 |  |  | $ | 0.17 |
Options granted |  |  | – |  |  |  | – |
Options exercised |  |  | (250,000 | ) |  |  | 0.08 |
Options cancelled |  |  | (4,773,000 | ) |  |  | 0.26 |
Options outstanding, December 31, 2022 |  |  | 26,057,601 |  |  | $ | 0.15 |
Options granted |  |  | – |  |  |  | – |
Options exercised |  |  | – |  |  |  | – |
Options cancelled |  |  | (300,446 | ) |  |  | 0.72 |
Options outstanding, December 31, 2023 |  |  | 25,757,155 |  |  | $ | 0.14 |
The weighted average exercise prices, remaining contractual lives for options granted, exercisable, and expected to vest as of December 31, 2023, were as follows: As of December 31, 2023, the market price of the Company’s stock was $0.06 per share. At December 31, 2023 the aggregate intrinsic value of the options outstanding was $115,000. Future unamortized compensation expense on the unvested outstanding options at December 31, 2023 is $0.
Schedule of options outstanding by per share price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Outstanding Options |  |  | Exercisable Options |
Option Exercise Price Per Share |  | Shares |  |  | Life (Years) |  | Weighted Average Exercise Price |  |  | Shares |  |  | Weighted Average Exercise Price |
$0.02 - $0.24 |  |  | 22,055,551 |  |  | 4.1 |  | $ | 0.10 |  |  |  | 22,055,551 |  |  | $ | 0.10 |
$0.25 - $0.49 |  |  | 3,238,552 |  |  | 2.7 |  |  | 0.36 |  |  |  | 3,238,552 |  |  |  | 0.36 |
$0.50 - $0.99 |  |  | 463,052 |  |  | 0.4 |  |  | 0.85 |  |  |  | 463,052 |  |  |  | 0.85 |
|  |  | 25,757,155 |  |  | 3.9 |  | $ | 0.14 |  |  |  | 25,757,155 |  |  | $ | 0.14 |
Year Ending December 31, 2023 During the year ended December 31, 2023 did not issue options to employees, officers or members of the Board of Directors. Year Ending December 31, 2022 During the year ended December 31, 2022, the Company did not issue options to employees, officers or members of the Board of Directors. Warrants The following table summarizes certain information about the Company’s stock purchase warrants.
Schedule of warrants activity |  |  |  |  |  |  |  |
|  | Warrants |  |  | Weighted Avg. Exercise Price |
Warrants outstanding, December 31, 2021 |  |  | 19,977,149 |  |  | $ | 0.04 |
Warrants granted |  |  | 16,426,657 |  |  |  | 0.04 |
Warrants exercised |  |  | (14,483,825 | ) |  |  | 0.04 |
Warrants expired |  |  | (1,605,828 | ) |  |  | 0.04 |
Warrants outstanding, December 31, 2022 |  |  | 20,314,153 |  |  | $ | 0.04 |
Warrants granted |  |  | 12,482,410 |  |  |  | 0.07 |
Warrants exercised |  |  | (1,383,327 | ) |  |  | 0.04 |
Warrants expired |  |  | (13,459,997 | ) |  |  | 0.04 |
Warrants outstanding, December 31, 2023 |  |  | 17,953,239 |  |  | $ | 0.06 |
At December 31, 2023 the price of the Company’s common stock was $0.06 per share and the aggregate intrinsic value of the warrants outstanding was $145,000. As of December 31, 2023, 17,919,906 warrants were fully vested and 33,333 warrants vest in January 2024.
Schedule of warrants outstanding by per share price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Outstanding Warrants |  |  | Exercisable Warrants |
Warrant Exercise Price Per Share |  | Shares |  |  | Life (Years) |  | Weighted Average Exercise Price |  |  | Shares |  |  | Weighted Average Exercise Price |
$0.02 - $0.24 |  |  | 17,883,239 |  |  | 0.6 |  | $ | 0.06 |  |  |  | 17,849,906 |  |  | $ | 0.06 |
$0.25 - $0.49 |  |  | – |  |  | – |  |  | – |  |  |  | – |  |  |  | – |
$0.50 - $1.00 |  |  | 70,000 |  |  | 0.3 |  |  | 0.80 |  |  |  | 70,000 |  |  |  | 0.80 |
|  |  | 17,953,239 |  |  | 0.6 |  | $ | 0.06 |  |  |  | 17,919,906 |  |  | $ | 0.06 |
Year Ending December 31, 2023
| · | In March through September 2023, pursuant to terms of convertible notes issued, the Company granted warrants to purchase 11,715,748 shares of common stock with an exercise price of $0.07 per share, vesting immediately upon grant and expiring one year from the date of grant.
| · | In January through December 2023, pursuant to terms of consulting agreements, the Company granted warrants to purchase 766,662 shares of common stock with an exercise price of $0.03 to $0.13 per share, vesting up to one month from the date of grant and expiring one to two years from the date of grant. Total fair value of these options at grant date was approximately $35,000 determined using the Black-Scholes Option Pricing model with the following assumptions: life of 1 to 2 years; risk free interest rate of 0.73% to 5.07%; volatility of 182% to 245%; and dividend yield of 0%. During the year ended December 31, 2023, the Company recognized compensation expense of $37,000 based on the fair value of the warrants that vested.
Year Ending December 31, 2022
| · | In September 2022, pursuant to terms of convertible notes issued, the Company granted warrants to purchase 14,409,995 shares of common stock with an exercise price of $0.04 per share, vesting immediately upon grant and expiring one year from the date of grant.
| · | In January through December 2022, pursuant to terms of consulting agreements, the Company granted warrants to purchase 2,016,662 shares of common stock with an exercise price of $0.02 to $0.09 per share, vesting up to one month from the date of grant and expiring two to five years from the date of grant. Total fair value of these options at grant date was approximately $127,000 determined using the Black-Scholes Option Pricing model with the following assumptions: life of 2 to 5 years; risk free interest rate of 0.13% to 4.49%; volatility of 193% to 245%; and dividend yield of 0%. During the year ended December 31, 2022, the Company recognized compensation expense of $127,000 based on the fair value of the warrants that vested.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration